Rapid Micro Biosystems (RPID) Gains from Investment Securities (2020 - 2026)

Rapid Micro Biosystems (RPID) reported Gains from Investment Securities of -$70000.0 for Q1 2026, up 59.3% sequentially from -$172000.0 in Q4 2025.

Rapid Micro Biosystems (RPID) Gains from Investment Securities (2020 - 2026) Analysis & Trends

Rapid Micro Biosystems (RPID) has 4 years of Gains from Investment Securities data on file, last reported at -$70000.0 in Q1 2026.

For the quarter ending Q1 2026, Gains from Investment Securities changed N/A year-over-year to -$70000.0; the trailing twelve-month figure through Mar 2026 stood at -$242000.0 (changed N/A YoY), and the FY2025 full-year result was -$131000.0, changed N/A from the prior year.
Gains from Investment Securities improved to -$70000.0 in Q1 2026, from -$172000.0 in the prior quarter.
In the past five years, Gains from Investment Securities ranged from a high of -$70000.0 in Q1 2026 to a low of -$172000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	183.64 Bn	176.34 Bn	6.27 Bn
2	Stryker	129.04 Bn	126.16 Bn	3.81 Bn
3	Medtronic	109.04 Bn	99.82 Bn	6.41 Bn
4	Boston Scientific	68.54 Bn	67.08 Bn	3.61 Bn
5	Edwards Lifesciences	48.67 Bn	45.00 Bn	1.29 Bn
6	Dexcom	28.40 Bn	27.28 Bn	750.30 Mn
7	GE HealthCare Technologies	28.37 Bn	26.08 Bn	1.98 Bn
8	Smith & Nephew	26.92 Bn	26.34 Bn	-
9	Koninklijke Philips	25.48 Bn	22.36 Bn	2.07 Bn
10	Rapid Micro Biosystems	90.41 Mn	80.98 Mn	371,000.00

Download Data